Company: MIRM
Filing Date: 2025-08-12
Form Type: S-3ASR
Source: 0001193125-25-178937
Chunk: 40

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-3ASR
Chunk 40
---
 City, California 94404, or by telephoning us at (650) 667-4085. Any statement contained herein or in a document incorporated or deemed to be incorporated by reference into this document will be deemed to be modified or superseded for purposes of the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be incorporated by reference into this document modifies or supersedes the statement. 32

PROSPECTUS SUPPLEMENT (To Prospectus Dated August 12, 2025) Up to $200,000,000 Common Stock We have entered into a sales agreement, or the sales agreement, with Leerink Partners LLC, or Leerink Partners, and Cantor Fitzgerald & Co., or Cantor, relating to the sale of shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, under this prospectus supplement and the accompanying prospectus we may offer and sell shares of our common stock, $0.0001 par value per share, having an aggregate offering price of up to $200,000,000 from time to time through or to Leerink Partners and Cantor, acting as our sales agents. Our common stock is listed on the Nasdaq Global Market under the symbol “MIRM.” On August 11, 2025, the last reported sale price of our common stock on the Nasdaq Global Market was $65.87 per share. Sales of our common stock, if any, under this prospectus supplement and the accompanying prospectus may be made by any method deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Leerink Partners and Cantor will act as our sales agents, using commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by us, consistent with their normal trading and sales practices, on mutually agreed terms set forth in the sales agreement. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. The compensation to Leerink Partners and Cantor for sales of common stock sold pursuant to the sales agreement is up to 3.0% of the gross proceeds of the common stock sold through such sales agent. See “ Plan of Distribution” beginning on page S-13for additional information regarding the compensation to be paid to Leerink